Metronidazol release

Figure 9.7 Effect of palmitic acid (PA) on metronidazole release at 10 percent loading and 125 pm film thickness.

D. Campos-Aldrete, M. E., and Villafuerte-Robles, L. (1997), Influence of the viscosity grade and the particle size of HPMC on metronidazole release from matrix tablet, Ear. J. Pharm. Biopharm., 43,173-178. 

KRISHNAIAH Y S, SEETHA DEVI A, NAGESWARA RAO L, BHASKAR REDDY P R, KARTHIKEYAN R S, SATYANARAYANA V (2001) Guat gum as a carrier for colon specific delivery influence of metronidazole and tinidazole on in vitro release of albendazole from guar gum matrix tablets. J Pharm Pharm Sci. 4 235-43. 

Controlled and sustained drug delivery has recently begun to make an impression in the area of treatment of dental diseases. Many researchers have demonstrated that controlled delivery of antimicrobial agents, such as chlorhexidine [128-130], ofloxacin [131-133], and metronidazole [134], can effectively treat and prevent periodontitis. The incidence of dental caries and formation of plaque can also be reduced by controlled delivery of fluoride [135,136]. Delivery systems used are film-forming solutions [129,130], polymeric inserts [132], implants, and patches. Since dental disease is usually chronic, sustained release of therapeutic agents in the oral cavity would obviously be desirable. 

Sulfasalazine is more effective when Crohn s disease involves the colon. Mesalamine derivatives (such as Pentasa or Asacol) that release mesalamine in the small bowel may be more effective than sulfasalazine for deal involvement. Steroids are frequently used for the treatment of active Crohn s disease, particularly with more severe presentations, or in those patients unresponsive to aminosalicylates. Budesonide is a viable first-line option for patients with mdd to moderate deal or right-sided disease. Systemic steroids induce remission in up to 70% of patients and should be reserved for patients with moderate to severe disease who have faded aminosahcylates or budesonide. Metronidazole (given orally up to 20 mg/kg/day) may be useful in some patients with Crohn s disease, particularly in patients with colonic or deocolonic involvement or those with perineal disease. The combination of metronidazole with ciprofloxacin is efficacious in some patients. 

Figure 8.35 Characteristics of in vivo polymer erosion and metronidazole (MTZ) release from 50/50 CAP/Pluronic LI 01 films (with 10% metronidazole loading) in a dorsal rat model.

Jones, C.E., Preparation and Characterisation of Polymer Films for the Release of Metronidazole, Ph.D. thesis, School of Pharmacy, University of London, 1990. 

An improvement of medical devices based on bacterial polymers by the encapsulation of different drugs, opens up the wide prospects in applications for these new devices with pharmacological activity in medicine. PHB polymer was used as a drug delivery matrix for sustaining the release of various drugs such as dipyridamole [DP], indomethacin and antibiotics (rifampicin, metronidazole, ciprofloxacin, levofloxacin), anti-inflammatory drugs (flurbiprofen, dexamethasone, prednisolone), and antitumor drugs (paclitaxel) [132]. 

Metronidazole Verapamil drug and lipids inducing complex dissociation and fast drug release [89]... 

Ampicillin and rifampicin markedly reduce the colonic release of 5-aminosalicylate (the active drug) from sulfasalazine. Metronidazole appears not to interact adversely with sulfasalazine. 

---